Laboratory for Microbiology and Infection Control, Amphia Hospital, PO Box 90158 4800 RK, Breda, The Netherlands.
Eur J Clin Microbiol Infect Dis. 2010 May;29(5):503-7. doi: 10.1007/s10096-010-0886-2. Epub 2010 Feb 26.
The in vitro activity of tigecycline was determined using a well-defined collection of methicillin-resistant Staphylococcus aureus (MRSA) isolates (n = 202), including 33 livestock-associated strains. Susceptibility testing was performed using the Etest system. Among the 202 MRSA strains, three (1.5%) had a minimum inhibitory concentration (MIC) value for tigecycline greater than 0.5 mg/l, which are considered to be resistant. When these strains were tested using Iso-Sensitest medium, the MICs were substantially lower and no resistance was found. This discrepancy warrants further investigations into the preferred test conditions for tigecycline. In conclusion, tigecycline showed good activity against MRSA strains in vitro.
采用经过明确定义的耐甲氧西林金黄色葡萄球菌（MRSA）分离株（n=202）集合，包括 33 株来自牲畜的分离株，来确定替加环素的体外活性。使用 Etest 系统进行药敏试验。在 202 株 MRSA 菌株中，有 3 株（1.5%）替加环素的最小抑菌浓度（MIC）值大于 0.5mg/L，被认为是耐药的。当使用 Iso-Sensitest 培养基对这些菌株进行测试时，MIC 值显著降低，并未发现耐药性。这种差异需要进一步研究替加环素的首选测试条件。总之，替加环素对体外 MRSA 菌株显示出良好的活性。
